Pharmaceutical company Enlivex Therapeutics (ENLV) completed the initial dosing and follow-up of patients with psoriatic arthritis treated with Allocetra in November. This Phase I trial evaluates the safety, tolerability, and potential effectiveness of Allocetra as a treatment for psoriatic arthritis. The company notes there have been no adverse events following the first joint injections.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Enlivex Therapeutics notes the study will last for 12 months with primary endpoints focused on adverse events. Another endpoint will evaluate the reduction of pain following treatment with Allocetra. Company CEO Dr. Oren Hershkovitz said the trial “potentially presents a substantial market opportunity for Enlivex.”
ENLV stock is up 2.86% as of this writing and has increased 2.91% over the last three months.
